pharmaphorum February 19, 2024
Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous infusion pump, according to NHS England.
Produodopa (foslevodopa/foscarbidopa) can now be used only for patients in the later stages of Parkinson’s who have stopped responding to standard oral treatment and may have to take more than 20 tablets a day – or receive therapy via a feeding tube – to try to control symptoms.
The treatment takes the form of a small and portable infusion pump that delivers the active ingredients over a 24-hour period and can be refilled at home by patients or their carers. AbbVie also supplies the feeding tube product, called...
Today's Sponsors
Today's Sponsor